Class information for:
Level 1: BENEFIT RISK//BENEFIT RISK ASSESSMENT//BENEFIT RISK COMMUNICATION

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
30020 176 25.7 52%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
1 4 ECONOMICS//EDUCATION & EDUCATIONAL RESEARCH//PSYCHOL 3876184
320 3       AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION//MEDICATION ERRORS//AMERICAN JOURNAL OF HOSPITAL PHARMACY 39312
2978 2             PHARMACOVIGILANCE//ADVERSE DRUG REACTIONS//DRUG SAFETY 2605
30020 1                   BENEFIT RISK//BENEFIT RISK ASSESSMENT//BENEFIT RISK COMMUNICATION 176

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BENEFIT RISK authKW 1837863 14% 42% 25
2 BENEFIT RISK ASSESSMENT authKW 651151 10% 22% 17
3 BENEFIT RISK COMMUNICATION authKW 346994 1% 100% 2
4 BENEFIT RISK EVALUAT address 346994 1% 100% 2
5 BENEFIT RISK METHODOLOGIES authKW 346994 1% 100% 2
6 CUSTOM MADE MEDICINE authKW 346994 1% 100% 2
7 GLOBAL REGULATORY AFFAIRS NEUROSCI address 346994 1% 100% 2
8 PHARMACOVIGILANCE MED SAFETY address 346994 1% 100% 2
9 REGULATORY AFFAIRS EUROPE address 346994 1% 100% 2
10 BENEFIT HARM ASSESSMENT authKW 231328 1% 67% 2

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Medical Informatics 3337 17% 0% 30
2 Health Care Sciences & Services 1846 22% 0% 39
3 Statistics & Probability 1657 24% 0% 42
4 Pharmacology & Pharmacy 1626 56% 0% 98
5 Mathematical & Computational Biology 866 13% 0% 23
6 Public, Environmental & Occupational Health 293 18% 0% 31
7 Health Policy & Services 236 6% 0% 11
8 Medicine, Research & Experimental 50 7% 0% 13
9 Toxicology 20 4% 0% 7
10 Economics 13 4% 0% 7

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BENEFIT RISK EVALUAT 346994 1% 100% 2
2 GLOBAL REGULATORY AFFAIRS NEUROSCI 346994 1% 100% 2
3 PHARMACOVIGILANCE MED SAFETY 346994 1% 100% 2
4 REGULATORY AFFAIRS EUROPE 346994 1% 100% 2
5 CLIN DEV BIOSTAT 1 231328 1% 67% 2
6 REGULATORY EXCELLENCE 231328 1% 67% 2
7 AUTON PHARMACOVIGILANCE 173497 1% 100% 1
8 BENEFIT RISK ASSESSMENT 173497 1% 100% 1
9 CLIN GENET GENET ECON 173497 1% 100% 1
10 CLIN REPORTING SYST 173497 1% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 THERAPEUTIC INNOVATION & REGULATORY SCIENCE 154823 10% 5% 18
2 DRUG INFORMATION JOURNAL 51207 10% 2% 18
3 STATISTICS IN BIOPHARMACEUTICAL RESEARCH 46059 5% 3% 9
4 PHARMACEUTICAL STATISTICS 21134 5% 2% 8
5 JOURNAL OF BIOPHARMACEUTICAL STATISTICS 15358 5% 1% 9
6 PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 10810 7% 1% 12
7 CLINICAL TRIALS 3733 2% 1% 4
8 VALUE IN HEALTH 2781 3% 0% 5
9 DRUG SAFETY 2072 3% 0% 5
10 CLINICAL PHARMACOLOGY & THERAPEUTICS 1899 5% 0% 8

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 BENEFIT RISK 1837863 14% 42% 25 Search BENEFIT+RISK Search BENEFIT+RISK
2 BENEFIT RISK ASSESSMENT 651151 10% 22% 17 Search BENEFIT+RISK+ASSESSMENT Search BENEFIT+RISK+ASSESSMENT
3 BENEFIT RISK COMMUNICATION 346994 1% 100% 2 Search BENEFIT+RISK+COMMUNICATION Search BENEFIT+RISK+COMMUNICATION
4 BENEFIT RISK METHODOLOGIES 346994 1% 100% 2 Search BENEFIT+RISK+METHODOLOGIES Search BENEFIT+RISK+METHODOLOGIES
5 CUSTOM MADE MEDICINE 346994 1% 100% 2 Search CUSTOM+MADE+MEDICINE Search CUSTOM+MADE+MEDICINE
6 BENEFIT HARM ASSESSMENT 231328 1% 67% 2 Search BENEFIT+HARM+ASSESSMENT Search BENEFIT+HARM+ASSESSMENT
7 PATHODYNAMICS 231328 1% 67% 2 Search PATHODYNAMICS Search PATHODYNAMICS
8 BENEFIT RISK ANALYSIS 180718 3% 21% 5 Search BENEFIT+RISK+ANALYSIS Search BENEFIT+RISK+ANALYSIS
9 ADVERSE DRUG REACTION SURVEILLANCE 173497 1% 100% 1 Search ADVERSE+DRUG+REACTION+SURVEILLANCE Search ADVERSE+DRUG+REACTION+SURVEILLANCE
10 ADVERSE EVEN IS 173497 1% 100% 1 Search ADVERSE+EVEN+IS Search ADVERSE+EVEN+IS

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 PIGNATTI, F , ASHBY, D , BRASS, EP , EICHLER, HG , FREY, P , HILLEGE, HL , HORI, A , LEVITAN, B , LIBERTI, L , LOEFSTEDT, RE , ET AL (2015) STRUCTURED FRAMEWORKS TO INCREASE THE TRANSPARENCY OF THE ASSESSMENT OF BENEFITS AND RISKS OF MEDICINES: CURRENT STATUS AND POSSIBLE FUTURE DIRECTIONS.CLINICAL PHARMACOLOGY & THERAPEUTICS. VOL. 98. ISSUE 5. P. 522 -533 9 90% 5
2 WITTES, J , CROWE, B , CHUANG-STEIN, C , GUETTNER, A , HALL, D , JIANG, Q , ODENHEIMER, D , XIA, HA , KRAMER, J , (2015) THE FDA'S FINAL RULE ON EXPEDITED SAFETY REPORTING: STATISTICAL CONSIDERATIONS.STATISTICS IN BIOPHARMACEUTICAL RESEARCH. VOL. 7. ISSUE 3. P. 174 -190 9 90% 2
3 MT-ISA, S , OUWENS, M , ROBERT, V , GEBEL, M , SCHACHT, A , HIRSCH, I , (2016) STRUCTURED BENEFIT-RISK ASSESSMENT: A REVIEW OF KEY PUBLICATIONS AND INITIATIVES ON FRAMEWORKS AND METHODOLOGIES.PHARMACEUTICAL STATISTICS. VOL. 15. ISSUE 4. P. 324 -332 10 71% 1
4 MT-ISA, S , HALLGREEN, CE , WANG, N , CALLREUS, T , GENOV, G , HIRSCH, I , HOBBIGER, SF , HOCKLEY, KS , LUCIANI, D , PHILLIPS, LD , ET AL (2014) BALANCING BENEFIT AND RISK OF MEDICINES: A SYSTEMATIC REVIEW AND CLASSIFICATION OF AVAILABLE METHODOLOGIES.PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. VOL. 23. ISSUE 7. P. 667 -678 23 30% 16
5 WALKER, S , MCAUSLANE, N , LIBERTI, L , LEONG, J , SALEK, S , (2015) A UNIVERSAL FRAMEWORK FOR THE BENEFIT-RISK ASSESSMENT OF MEDICINES: IS THIS THE WAY FORWARD?.THERAPEUTIC INNOVATION & REGULATORY SCIENCE. VOL. 49. ISSUE 1. P. 17 -25 7 100% 5
6 BENDER, R , BECKMANN, L , LANGE, S , (2016) BIOMETRICAL ISSUES IN THE ANALYSIS OF ADVERSE EVENTS WITHIN THE BENEFIT ASSESSMENT OF DRUGS.PHARMACEUTICAL STATISTICS. VOL. 15. ISSUE 4. P. 292 -296 8 67% 1
7 CHUANG-STEIN, C , XIA, HA , (2013) THE PRACTICE OF PRE-MARKETING SAFETY ASSESSMENT IN DRUG DEVELOPMENT.JOURNAL OF BIOPHARMACEUTICAL STATISTICS. VOL. 23. ISSUE 1. P. 3 -25 9 60% 0
8 BUJAR, M , MCAUSLANE, N , SALEK, S , WALKER, S , (2016) QUALITY OF REGULATORY DECISION-MAKING PRACTICES: ISSUES FACING COMPANIES AND AGENCIES.THERAPEUTIC INNOVATION & REGULATORY SCIENCE. VOL. 50. ISSUE 4. P. 487 -495 5 100% 0
9 MA, HJ , JIANG, Q , CHUANG-STEIN, C , EVANS, SR , HE, WL , QUARTEY, G , SCOTT, J , WEN, SH , ARANI, R , (2016) CONSIDERATIONS ON ENDPOINT SELECTION, WEIGHTING DETERMINATION, AND UNCERTAINTY EVALUATION IN THE BENEFIT-RISK ASSESSMENT OF MEDICAL PRODUCT.STATISTICS IN BIOPHARMACEUTICAL RESEARCH. VOL. 8. ISSUE 4. P. 417 -425 11 42% 0
10 DAVIS, B , SOUTHWORTH, H , (2016) STATISTICAL ANALYSIS OF CUMULATIVE SERIOUS ADVERSE EVENT DATA FROM DEVELOPMENT SAFETY UPDATE REPORTS.THERAPEUTIC INNOVATION & REGULATORY SCIENCE. VOL. 50. ISSUE 2. P. 188 -194 7 64% 0

Classes with closest relation at Level 1


Rank Class id link
1 11124 NUMERACY//RISK COMMUNICATION//RISK LITERACY
2 26445 DRUG LAG//JAPANESE CLINICAL TRIALS//GLOBAL DRUG DEVELOPMENT
3 4114 PHARMACOVIGILANCE//ADVERSE DRUG REACTIONS//DRUG SAFETY
4 27289 LOG BINOMIAL MODEL//LOG BINOMIAL REGRESSION//PREVALENCE RATIO
5 7043 RESEARCH SYNTHESIS METHODS//MIXED TREATMENT COMPARISON//NETWORK META ANALYSIS
6 16184 ORPHAN DRUGS//RARE DISEASES//ORPHAN DRUG ACT
7 32356 DRUG SHORTAGES//JAMES PARKINSON//MEDICINE SHORTAGES
8 12314 COMPETING RISKS//MULTISTATE MODEL//CUMULATIVE INCIDENCE FUNCTION
9 30357 COMPOSITE ENDPOINTS//WIN RATIO//WORST RANK SCORES
10 9848 UNCONDITIONAL TEST//2 X 2 TABLES//FISHERS EXACT TEST

Go to start page